PMID- 37975315
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240226
IS  - 1460-2202 (Electronic)
IS  - 0271-3683 (Linking)
VI  - 49
IP  - 3
DP  - 2024 Mar
TI  - Association between Oral Active-Matrix Metalloproteinase-8 Levels and Subretinal 
      Fibrosis among Wet Age-Related Macular Degeneration Patients.
PG  - 288-294
LID - 10.1080/02713683.2023.2280442 [doi]
AB  - PURPOSE: Periodontitis causes low-grade systemic inflammation and has been 
      associated with elevated active-matrix metalloproteinase (aMMP-8) levels, 
      blood-ocular barrier breakdown and a risk of wet age-related macular 
      degeneration. To assess the association between aMMP-8 levels and macular status 
      among patients with wet age-related macular degeneration (AMD). METHODS: Patients 
      on anti-VEGF treatment for wet AMD were enrolled for oral aMMP-8 rinse test in 
      Mehilainen Private Hospital, Helsinki, Finland. Macular status was examined from 
      spectral-domain optical coherence tomography (SD-OCT) scans by a medical retina 
      specialist and aMMP-8 levels were analyzed with chairside point-of-care oral 
      rinse (PerioSafe(R)) test and real-time quantitated by a dentist using the 
      ORALyzer(R)- reader with a 10 ng/ml cut-off for aMMP-8 activity. RESULTS: Elevated 
      aMMP-8 levels were found in 10 out of 32 patients. Age, gender, anti-VEGF 
      (bevacizumab or aflibercept) distribution, cumulative number of anti-VEGF 
      injections and treatment interval were comparable between patients with aMMP-8 
      levels below and above the point-of-care level. Macular status differed in regard 
      to aMMP-8 activity; among patients with aMMP-8 levels below the point-of-care 
      subretinal fibrosis was found in 6 out of 22 eyes, whereas among patients with 
      aMMP-8 levels above the point-of-care subretinal fibrosis was found in 8 out of 
      10 eyes (p = 0.005). Respectively, the mean thickness of subretinal fibrosis at 
      fovea was 19.5 +/- 44.1 and 92.3 +/- 78.3 microm (p = 0.018). No differences were found 
      in the presence and in the area of geographic atrophy, or fluid distribution, 
      whereas thicknesses of serous pigment epithelial detachment (65.5 +/- 99.5 and 
      12.9 +/- 27.9 microm, p = 0.038) and neuroretina (204.2 +/- 57.8 microm and 143.0 +/- 43.7 microm, 
      p = 0.006) were greater in the eyes of patients with physiological aMMP-8 levels 
      compared to those with elevated aMMP-8 levels. CONCLUSION: Elevated aMMP-8 levels 
      may account for subretinal fibrosis formation in wet AMD.
FAU - Karesvuo, Minna
AU  - Karesvuo M
AD  - Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.
AD  - Health Services Dental Care, City of Helsinki, Helsinki, Finland.
AD  - Department of Ophthalmology, Mehilainen Private Hospital, Helsinki, Finland.
FAU - Sorsa, Timo
AU  - Sorsa T
AD  - Department of Oral and Maxillofacial Diseases, University of Helsinki and 
      Helsinki University Hospital, Helsinki, Finland.
AD  - Department of Medicine and Dental Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Tuuminen, Raimo
AU  - Tuuminen R
AD  - Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.
AD  - Department of Ophthalmology, Mehilainen Private Hospital, Helsinki, Finland.
AD  - Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 
      Israel.
AD  - Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland.
LA  - eng
PT  - Journal Article
DEP - 20231117
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.34 (Matrix Metalloproteinase 8)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Humans
MH  - *Angiogenesis Inhibitors/therapeutic use
MH  - Vascular Endothelial Growth Factor A/therapeutic use
MH  - Matrix Metalloproteinase 8/therapeutic use
MH  - Retrospective Studies
MH  - Intravitreal Injections
MH  - *Wet Macular Degeneration/diagnosis/drug therapy/complications
MH  - Fibrosis
MH  - Tomography, Optical Coherence/methods
MH  - Subretinal Fluid
MH  - Ranibizumab
OTO - NOTNLM
OT  - Active MMP-8
OT  - blood-ocular-barrier breakdown
OT  - macular fibrosis
OT  - periodontitis
OT  - wet age-related macular degeneration
EDAT- 2023/11/17 15:22
MHDA- 2024/02/26 06:44
CRDT- 2023/11/17 06:31
PHST- 2024/02/26 06:44 [medline]
PHST- 2023/11/17 15:22 [pubmed]
PHST- 2023/11/17 06:31 [entrez]
AID - 10.1080/02713683.2023.2280442 [doi]
PST - ppublish
SO  - Curr Eye Res. 2024 Mar;49(3):288-294. doi: 10.1080/02713683.2023.2280442. Epub 
      2023 Nov 17.